Arena Pharmaceuticals Statistics
Share Statistics
Arena Pharmaceuticals has 0
shares outstanding. The number of shares has increased by 1.59%
in one year.
| Shares Outstanding | n/a |
| Shares Change (YoY) | 1.59% |
| Shares Change (QoQ) | 1.59% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -8.2 and the forward
PE ratio is null.
Arena Pharmaceuticals's PEG ratio is
-0.15.
| PE Ratio | -8.2 |
| Forward PE | n/a |
| PS Ratio | 94260.09 |
| Forward PS | n/a |
| PB Ratio | 7.56 |
| P/FCF Ratio | -9.73 |
| PEG Ratio | -0.15 |
Financial Ratio HistoryEnterprise Valuation
Arena Pharmaceuticals has an Enterprise Value (EV) of 4.91B.
| EV / Sales | 90864.52 |
| EV / EBITDA | -8.06 |
| EV / EBIT | -10.86 |
| EV / FCF | -9.38 |
Financial Position
The company has a current ratio of 8.59,
with a Debt / Equity ratio of 0.06.
| Current Ratio | 8.59 |
| Quick Ratio | 8.59 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | -0.07 |
| Debt / FCF | -0.08 |
| Interest Coverage | -147.22 |
Financial Efficiency
Return on Equity is -92.18% and Return on Invested Capital is -86.28%.
| Return on Equity | -92.18% |
| Return on Assets | -79.09% |
| Return on Invested Capital | -86.28% |
| Revenue Per Employee | $120.54 |
| Profits Per Employee | $-1,385,250 |
| Employee Count | 448 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 4.16M |
| Effective Tax Rate | -0.67% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is 0.55, so Arena Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.55 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 79.03 |
| Average Volume (20 Days) | 1,472,638 |
Income Statement
In the last 12 months, Arena Pharmaceuticals had revenue of 54K
and earned -620.59M
in profits. Earnings per share was -11.33.
| Revenue | 54K |
| Gross Profit | 54K |
| Operating Income | -612.27M |
| Net Income | -620.59M |
| EBITDA | -608.4M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -11.33 |
Full Income StatementBalance Sheet
The company has 224.57M in cash and 41.21M in
debt, giving a net cash position of 183.36M.
| Cash & Cash Equivalents | 224.57M |
| Total Debt | 41.21M |
| Net Cash | 183.36M |
| Retained Earnings | -2.12B |
| Total Assets | n/a |
| Working Capital | n/a |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -452.02M
and capital expenditures -70.99M, giving a free cash flow of -523M.
| Operating Cash Flow | -452.02M |
| Capital Expenditures | -70.99M |
| Free Cash Flow | -523M |
| FCF Per Share | -9.55 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -1133840.74% and -1149244.44%.
| Gross Margin | 100% |
| Operating Margin | -1133840.74% |
| Pretax Margin | -1141542.59% |
| Profit Margin | -1149244.44% |
| EBITDA Margin | -1126670.37% |
| EBIT Margin | -1133840.74% |
| FCF Margin | -968525.93% |
